In October 2021, the WHO recommended the world’s first malaria vaccine—RTS,S/AS01—to prevent malaria in children living in areas with moderate-to-high transmission in sub-Saharan Africa (SSA). A second malaria vaccine, R21/Matrix-M, was recommended for use in October 2023 and added to the WHO list of prequalified vaccines in December 2023. This study analysis assessed the country status of implementation and delivery strategies for RTS,S/AS01 by searching websites for national malaria policies, guidelines and related documents. Direct contact with individuals working in malaria programmes was made to obtain documents not publicly available. 10 countries had documents with information relating to malaria vaccine implementation, 7 referencing RTS,S/AS01 and 3 (Burkina Faso, Kenya and Nigeria) referencing RTS,S/AS01 and R21/Matrix-M. Five other countries reported plans for malaria vaccine roll-out without specifying which vaccine. Ghana, Kenya and Malawi, which piloted RTS,S/AS01, have now integrated the vaccine into routine immunisation services. Cameroon and Burkina Faso are the first countries outside the pilot countries to incorporate the vaccine into national immunisation services. Uganda plans a phased RTS,S/AS01 introduction, while Guinea plans to first pilot RTS,S/AS01 in five districts. The RTS,S/AS01 schedule varied by country, with the first dose administered at 5 or 6 months in all countries but the fourth dose at either 18, 22 or 24 months. SSA countries have shown widespread interest in rolling out the malaria vaccine, the Global Alliance for Vaccines and Immunization having approved financial support for 20 of 30 countries which applied as of March 2024. Limited availability of RTS,S/AS01 means that some approved countries will not receive the required doses. Vaccine availability and equity must be addressed even as R21/Matrix-M becomes available.
Objective To assess the quality of available and accessible national Clinical Practice Guidelines (CPGs) in Kenya using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) tool. Methods We searched the websites of the Kenyan Ministry of Health, professional associations and contacted experts in relevant organisations. Our scope was guidelines on maternal, neonatal, nutritional disorders, injuries, communicable and non-communicable diseases in Kenya published in the last 5 years until 30 June 2022. Study selection and data extraction were done by three independent reviewers with disagreements resolved via discussion or with a senior reviewer. We conducted a quality assessment using the online English version of AGREE II tool across six domains. Descriptive statistics were analysed using Stata software V.17. The primary outcome was the methodological quality of the included CPGs assessed by the AGREE II tool score. Results We retrieved 95 CPGs and included 24 in the analysis after screening for eligibility. The CPGs scored best in clarity of presentation and least in the rigour of development. In descending order, the appraisal scores (mean and CI) per domain were as follows: Clarity of presentation 82.96% (95% CI 78.35% to 87.57%) with all guidelines scoring above 50%. Scope and purpose 61.75% (95% CI 54.19% to 69.31%) with seven guidelines scoring less than 50%. Stakeholder involvement 45.25% (95% CI 40.01% to 50.49%) with 16 CPGs scoring less than 50%. Applicability domain 19.88% (95% CI 13.32% to 26.43%) with only one CPG scoring above 50%. Editorial independence 6.92% (95% CI 3.47% to 10.37%) with no CPG scoring above 50% and rigour of development 3% (95% CI 0.61% to 5.39%) with no CPG scoring at least 50%. Conclusion Our findings suggest that the quality of CPGs in Kenya is limited mainly by the rigour of development, editorial independence, applicability and stakeholder involvement. Training initiatives on evidence-based methodology among guideline developers are needed to improve the overall quality of CPGs for better patient care.
8 July 2025 in African Journal of Primary Health Care & Family Medicine
Background: Gender intersects with multiple forms of socio-cultural, economic and health system factors to influence the overall care-seeking experiences of caregivers. Aim: This study aimed to understand the multiple gendered intersecting factors that shape women caregivers care-seeking experiences for children with probable pneumonia. Setting: The study was conducted in Karemo, Siaya County in western Kenya. Methods: In-depth interviews (IDI), participant observation and informal interviews were utilised. The IDI was conducted among purposively selected 12 caregivers out of which 11 were enrolled in participant observation. Data were managed and analysed using Dedoose and hermeneutic phenomenology, respectively. Results: Women juggle household chores, caregiving and income-generating activities, which sometimes led them to decline child’s hospitalisation because of competing household responsibilities. At the hospital, women experienced long waiting times, poor communication, unfavourable conditions, unfriendly staff and lack of drugs. Some women reported challenges in accessing money from their husbands for their child’s healthcare. They were often required to make difficult choices, such as prioritising work because of financial constraints, prioritising other children because of lack of external support, or opting for over-the-counter medication because of convenience, drug shortages or long waiting times at the hospital. Conclusion: Lived experiences are shaped by women’s daily realities and constraints. To improve women’s caregiving experiences, a holistic approach that considers the multiple dimensions of caregivers’ lives and gendered dynamics is recommended. Contribution: This study’s findings emphasise the necessity of a holistic approach when developing intervention geared towards improving healthcare-seeking behaviour by considering the subtler factors beyond structural, social and economic influences.
Objective To perform critical methodological assessments on designs, outcomes, quality and implementation limitations of studies evaluating the impact of malaria rapid diagnostic tests (mRDTs) on patient-important outcomes in sub-Saharan Africa. Design A systematic review of study methods. Data sources MEDLINE, EMBASE, Cochrane Library, African Index Medicus and clinical trial registries were searched up to May 2022. Eligibility criteria Primary quantitative studies that compared mRDTs to alternative diagnostic tests for malaria on patient-important outcomes within sub-Sahara Africa. Data extraction and synthesis Studies were sought by an information specialist and two independent reviewers screened for eligible records and extracted data using a predesigned form using Covidence. Methodological quality was assessed using the National Institutes of Health tools. Descriptive statistics and thematic analysis guided by the Supporting the Use of Research Evidence framework were used for analysis. Findings were presented narratively, graphically and by quality ratings. Results Our search yielded 4717 studies, of which we included 24 quantitative studies; (15, 62.5%) experimental, (5, 20.8%) quasi-experimental and (4, 16.7%) observational studies. Most studies (17, 70.8%) were conducted within government-owned facilities. Of the 24 included studies, (21, 87.5%) measured the therapeutic impact of mRDTs. Prescription patterns were the most reported outcome (20, 83.3%). Only (13, 54.2%) of all studies reported statistically significant findings, in which (11, 45.8%) demonstrated mRDTs’ potential to reduce over-prescription of antimalarials. Most studies (17, 70.8%) were of good methodological quality; however, reporting sample size justification needs improvement. Implementation limitations reported were mostly about health system constraints, the unacceptability of the test by the patients and low trust among health providers. Conclusion Impact evaluations of mRDTs in sub-Saharan Africa are mostly randomised trials measuring mRDTs’ effect on therapeutic outcomes in real-life settings. Though their methodological quality remains good, process evaluations can be incorporated to assess how contextual concerns influence their interpretation and implementation. PROSPERO registration number CRD42018083816.
Background: Access to rapid diagnostic tests for malaria (mRDTs) has significantly increased in sub-Saharan Africa, but this region still bears the largest burden of Malaria. Assessing the impact of mRDTs on patient-important outcomes is essential in effectively guiding their future evaluation and programmatic scale-up.Objective: We aim to critically assess the study designs, outcome measures, methodological quality and implementation challenges of studies that evaluate the impact of mRDTs compared to other malaria diagnostic tests on patient-important outcomes among persons suspected of malaria in sub-Sahara Africa through a systematic review of the literature.Methods and Analysis: We will search MEDLINE, EMBASE, Cochrane Library, African Index Medicus and clinical trial registries from inception until June 2022. We will include a primary randomized or non-randomized study that compares the impact of mRDTs to clinical diagnosis, microscopy and polymerase chain reaction (PCR) on patient-important outcomes such as time to diagnosis/turn-around time, time to initiation of therapy, time to resolution of malaria-associated symptoms, morbidity and mortality in both adults and children. We will also include quantitative studies with an additional qualitative component (mixed methods studies) to assess the implementation challenges of mRDTs. We will assess the methodological quality of included studies using National Institutes of Health (NIH) quality assessment tools for experimental and observational studies. We will use the Mixed methods appraisal tool (MMAT) version 2018 for mixed methods studies. We will analyse our results through descriptive statistics and thematic content analysis and present our findings narratively, graphically and by quality ratings.Registration: This protocol is registered with the International Prospective Register of Systematic Reviews (PROSPERO), registration number CRD42018083816.Dissemination: We intend to publish the outcome of our review in a peer-reviewed journal and develop a valuable and accessible result summary.
Background: Clinical practice guidelines (CPGs) play a significant role in informing clinical decision-making and improving the quality of health care. Kenya, a lower-middle income country, is faced with a high disease burden amidst a shortage of health workers. Well-developed and implemented CPGs are essential in guiding quality healthcare practices.Objective: We aim to assess the quality of available and accessible national CPGs in Kenya, make recommendations on their development, adaptation and implementation to improve health outcomes. Methods: We will use the Appraisal of Guidelines for Research and Evaluation II (AGREE II) tool to assess the methodological quality of available and accessible CPGs. Our focus will be guidelines on diseases or conditions under the broad categories of maternal disorders, neonatal disorders, nutritional disorders, injuries, communicable and non-communicable diseases in Kenya. We will search websites and databases of the Kenyan Ministry of Health, health associations of Kenya and contact relevant experts or personnel in these organizations. We will also use the google search engine to identify any eligible guidelines. Three reviewers will independently conduct data extraction and quality assessment of the guidelines using the English version of AGREE II tool with six domains (scope and purpose, stakeholder involvement, rigour of development, clarity of presentation, applicability, and editorial independence). Analysis: We will use descriptive statistics to analyse the results and present findings as quality scores. The results of the 23 items and the six domains in the AGREE II tool will be presented in mean and standard deviations.Dissemination: We will disseminate the findings of this study through publication in a peer-reviewed journal, presentations at scientific conferences and relevant healthcare stakeholders meetings.